Method for detecting subject, and immunoassay instrument and monoclonal antibody used in said method

By identifying monoclonal antibody combinations and antigen binding fragments of more than two types of antigens, combined with the optimized immunoassay instrument design, the problem of low sensitivity of monoclonal antibodies in immunoassays is solved, and the detection effect of high sensitivity is achieved.

CN118914547APending Publication Date: 2024-11-08DENKA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410942217.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2015-05-29
Filing Date
2016-05-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Monoclonal antibodies have low sensitivity in immunoassays, making it difficult to achieve high sensitivity detection.

Method used

Immunoassays were performed using monoclonal antibodies that recognize more than two types of antigens or their antigen-binding fragments, and detection sensitivity was improved by combining polyclonal antibodies, and immunoassay instruments containing cured monoclonal antibodies were designed to optimize antigen-antibody reactions.

Benefits of technology

The sensitivity of immunoassays has been significantly improved, overcome the problem of low sensitivity of monoclonal antibodies, and provides novel monoclonal antibodies and instruments for Mycoplasma pneumoniae detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914547A_ABST
    Figure CN118914547A_ABST
Patent Text Reader

Abstract

Disclosed is a novel detection method for detecting a subject by an immunoassay in which a monoclonal antibody is used, although the low sensitivity due to the use of the monoclonal antibody is improved. A method for detecting a test subject, in which two or more types of antigens are present for detection of the test subject, is carried out by an immunoassay method such as a sandwich method using a monoclonal antibody or an antigen-binding fragment thereof that recognizes the two or more types of antigens.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of a patent application filed on May 27, 2016 (priority date May 29, 2015), with original application number 201680031403.X (international application number PCT / JP2016 / 065683), and invention name “Detection method of an object to be tested, and immunoassay instrument and monoclonal antibody used in the method”. Technical Field

[0001] The present invention relates to a method for detecting pathogenic bacteria and other test objects by immunoassay, and an immunoassay instrument and monoclonal antibody used in the method. Background Art

[0002] Since monoclonal antibodies only recognize specific antigens, they are widely used in the detection of specific antigens. For example, Patent Document 1 describes a method for immunoassaying Mycoplasma pneumoniae, which is an immunoassay method based on a sandwich method in which a monoclonal antibody that recognizes the P30 protein of Mycoplasma pneumoniae is immobilized on a solid phase.

[0003] Prior art literature Patent Literature Patent document 1: WO2015 / 025968. Summary of the invention

[0004] Problems to be solved by the invention Polyclonal antibodies are antibodies that are a mixture of various antibodies that recognize various antigens or antigenic determinants. Since monoclonal antibodies have the property of only recognizing a specific region of a specific antigen, they are generally more specific than polyclonal antibodies. On the other hand, it is easy to imagine that monoclonal antibodies are at a disadvantage compared to polyclonal antibodies in terms of the types and total number of antigens that can bind to antibodies. This will result in low sensitivity in monoclonal antibodies and immunoassay methods and immunoassay instruments using them.

[0005] The object of the present invention is to provide a novel detection method, which is a method for detecting a test object by immunoassay, in which a monoclonal antibody is used, and the low sensitivity due to the use of the monoclonal antibody is improved. In addition, the object of the present invention is to provide an immunoassay instrument used in the detection method of the present invention. In addition, the object of the present invention is to provide a novel monoclonal antibody that can be used for the detection of Mycoplasma pneumoniae based on the method of the present invention.

[0006] Means for solving problems In order to make up for the low sensitivity of monoclonal antibodies, it is considered to use an immunoassay of multiple monoclonal antibodies. It is called the immunoassay of common ELISA and immunochromatography, and the amount of antibody that can be used depends on the area of ​​the ELISA plate or the immunochromatography stripe or the area of ​​the marker. In this case, compared with the situation of using a single monoclonal antibody, by using multiple monoclonal antibodies, the types and total number of antigens that can be combined with these antibodies form an advantage. Although there is no difference in the situation of excess antigen amount relative to the antibody amount used, when the antigen amount is insufficient relative to the antibody amount used, high sensitivity in the immunoassay can be brought.

[0007] However, since the amount of each monoclonal antibody used is less than that of a single monoclonal antibody, the probability of encounter between each specific antigen and antibody is reduced, and the reactivity per unit time is reduced. This is one of the factors that makes it difficult to achieve high sensitivity in immunoassays, and it is difficult to obtain satisfactory sensitivity.

[0008] As a result of intensive research, the inventors of the present application have found that the use of a monoclonal antibody having specificity and recognizing two or more types of antigens has excellent sensitivity compared to the conventional method of using a single or multiple monoclonal antibodies, thereby completing the present invention. In addition, the inventors have found that the immunoassay method using the monoclonal antibody has excellent sensitivity compared to the conventional immunoassay using the monoclonal antibody, thereby completing the present invention.

[0009] That is, the present invention provides a method for detecting a test object, which is a method for detecting a test object in which there are two or more antigens that can be detected as the test object, and the aforementioned method for detecting the test object is performed by an immunoassay method using a monoclonal antibody or an antigen-binding fragment thereof that recognizes the aforementioned two or more antigens. In addition, the present invention provides an immunoassay instrument, which is an immunoassay instrument for performing the above-mentioned method of the present invention, comprising a solid phase immobilized with the aforementioned monoclonal antibody or an antigen-binding fragment thereof. Furthermore, the present invention provides a monoclonal antibody that specifically reacts with the P1 protein and the P30 protein from Mycoplasma pneumoniae.

[0010] Effects of the Invention The method of the present invention has high specificity because monoclonal antibodies are used in immunoassays, and the low sensitivity due to the use of monoclonal antibodies is improved. In addition, the present invention provides an immunoassay instrument and a monoclonal antibody used in the novel detection method of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] [ Figure 1 ] is a diagram showing the results of studying the reactivity of the monoclonal antibody of the present invention prepared in the following Examples by immunoblotting.

[0012] [ Figure 2 ] is a diagram schematically showing a preferred embodiment of the immunochromatographic immunoassay instrument of the present invention. DETAILED DESCRIPTION

[0013] The object to be detected by the method of the present invention is an object to be detected that has two or more antigens that can be detected, and examples thereof include various pathogens such as bacteria, viruses, fungi, and rickettsia, but are not limited to these. In the following embodiment, the object to be detected is Mycoplasma pneumoniae, and the two or more antigens are P1 protein and P30 protein. It should be noted that even in the case of quantitative or semi-quantitative objects, since quantitative or semi-quantitative is inevitably accompanied by "detection", it is also included in the "detection" mentioned in the present invention.

[0014] In the method of the present invention, the immunoassay is performed using a monoclonal antibody or an antigen-binding fragment thereof that recognizes the above two or more antigens. Here, "recognition" means to react specifically, i.e., an antigen-antibody reaction. "Specificity" means that in a solution system in which a protein and the antibody are mixed, the antibody and the protein component of the antigen do not cause an antigen-antibody reaction at a detectable level, or even if some binding reaction or association reaction occurs, it only causes a significantly weaker reaction than the antigen-antibody reaction of the antibody and the antigen.

[0015] Based on the monoclonal antibody of the present invention, antigen-binding fragments with only the antigen-binding site separated can also be used in the method of the present invention. That is, the use of fragments (antigen-binding fragments) having specific antigen binding properties such as Fab, Fab', F(ab')2, single-chain antibodies (scFv) produced by known methods is also included in the scope of the present invention. In addition, the type of monoclonal antibodies is not limited to IgG, and may also be IgM or IgY.

[0016] The monoclonal antibody used in the method of the present invention can be obtained as follows: using a known immunological method, a complex or extract containing two or more target antigens, or one of the two or more antigens or their partial peptides is immunized to an immunized animal, and a hybridoma is prepared using the cells of the immunized animal to obtain it. There is no particular limitation on the length of the peptide used for immunization, and a peptide of 5 amino acids or more, more preferably 10 amino acids or more, can be preferably used as an immunogen. The immunogen can also be obtained from a culture medium, or by inserting a DNA encoding any antigen into a plasmid vector and introducing it into a host cell for expression. It is also possible to express any antigen or its partial peptide as an immunogen with the protein exemplified below in the form of a fusion protein, and use it as an immunogen in a purified or unpurified state. In the preparation of fusion proteins, those skilled in the art can use glutathione-S-transferase (GST), maltose binding protein (MBP), thioredoxin (TRX), Nus tag, S tag, HSV tag, FRAG tag, polyhistidine tag, etc., which are commonly used as "protein expression, purification tags". Fusion proteins with these are preferably used as immunogens after any antigen or its partial peptide portion is cleaved from the tag portion other than the antigen or the partial peptide portion thereof using a digestive enzyme and separated and purified.

[0017] Monoclonal antibodies can be easily prepared from immunized animals by the well-known method of Kohler et al. (Kohler et al., Nature, vol. 256, p495-497 (1975)). That is, antibody-producing cells such as spleen cells or lymphocytes are recovered from immunized animals, fused with mouse myeloma cells by conventional methods to prepare hybridomas, and the obtained hybridomas are cloned by limiting dilution method, etc., and monoclonal antibodies that react with the antigen used for animal immunization are selected from the monoclonal antibodies produced by each cloned hybridoma.

[0018] Since the monoclonal antibody used in the method of the present invention is an antibody that recognizes more than two kinds of antigens, for the monoclonal antibody selected by such operation and recognizing one of the more than two kinds of antigens, the monoclonal antibody that recognizes the other antigen is further screened. In the case of using a monoclonal antibody that recognizes more than three kinds of antigens, the same screening can be further repeated to select the monoclonal antibody that recognizes each antigen. In the method of the present invention, a monoclonal antibody or an antigen-binding fragment thereof that recognizes both of the more than two kinds of antigens obtained by such operation is used. It should be noted that in order to enable the existence of monoclonal antibodies that recognize two kinds of antigens, the following various possibilities are considered: the situation of recognizing a region with high homology existing in different antigens between two kinds of antigens, the situation of recognizing a region with similar three-dimensional structures existing in different antigens, the situation of recognizing different antigens to form a complex and spanning the region of its adjacent parts, the situation of recognizing different antigens to form a complex and spanning the three-dimensional structure of its adjacent parts, etc. Therefore, the "method for detecting a subject having more than two kinds of antigens that can be detected as a subject" mentioned in the present invention is limited to the situation where monoclonal antibodies that recognize more than two kinds of antigens can be obtained. In addition, generally, since the more types of antigens to be recognized, the more difficult it is to obtain monoclonal antibodies that recognize them, it is preferred that the monoclonal antibodies recognize two types of antigens. It should be noted that in the following examples, monoclonal antibodies that recognize the P1 protein and the P30 protein of Mycoplasma pneumoniae were obtained through such screening.

[0019] Known immunoglobulin purification methods can be used to purify monoclonal antibodies from ascites or culture supernatant. For example, fractionation based on salting out using ammonium sulfate or sodium sulfate, PEG fractionation, ethanol fractionation, DEAE ion exchange chromatography, gel filtration, etc. can be enumerated. In addition, depending on the type of immune animal and monoclonal antibody, it can also be purified by affinity chromatography using a carrier that is combined with any one of protein A, protein G, and protein L.

[0020] In the immunoassay method of the present invention, the antigen-antibody reaction of the monoclonal antibody or its antigen-binding fragment (hereinafter, in the description before the embodiment, except for the case where it is clear from the context that this is not the case) produced by the above operation and the antigen-antibody reaction of the antigen in the specimen is measured. As an immunoassay method for the measurement, any method known to those skilled in the art, such as the competition method, agglutination method, immunoblotting method, immunostaining method, sandwich method, etc., can also be used. It should be noted that in the present invention, "measurement" also includes any one of quantitative, semi-quantitative, and detection.

[0021] As immunoassay, the sandwich method is preferred. The sandwich method itself is well known in the field of immunoassay, and can be performed, for example, by immunochromatography or ELISA. These sandwich methods themselves are all well known, and the method of the present invention can be performed by a well-known sandwich method except using the above-mentioned monoclonal antibody of the present invention that recognizes more than two kinds of antigens.

[0022] Two kinds of antibodies (antibodies and labeled antibodies solidified on a solid phase) that recognize antigens are used in the sandwich method, but in the method of the present invention, at least one of these two kinds of antibodies is the above-mentioned monoclonal antibody that recognizes more than two kinds of antigens. As described later, since the amount of antibodies that can be solidified per unit area is limited due to the antibodies solidified on the solid phase, in order to better achieve the purpose of the present invention, which is referred to as sensitivity enhancement, it is preferred to use the above-mentioned monoclonal antibodies that recognize more than two kinds of antigens at least on the solidified antibodies. It should be noted that among a single molecule or a single complex, in the case where there are at least two kinds of antigens recognized by the monoclonal antibody, a single kind of the monoclonal antibody can also be used as a solid phase antibody and a labeled antibody to carry out the sandwich method (refer to the following embodiments).

[0023] In immunoassays using the sandwich method as the detection principle, as the solid phase for fixing the antibody, all solid phases that can fix the antibody by known techniques can be used, for example, known solid phases such as porous films (membranes) with capillary action, particulate substances, test tubes, and resin plates can be arbitrarily selected. In addition, as substances for labeling antibodies, enzymes, radioactive isotopes, fluorescent substances, luminescent substances, colored particles, colloidal particles, etc. can be used. Even among the immunoassays based on the aforementioned various materials, in particular, from the viewpoint of simplicity and rapidity of clinical examinations, it is preferred to use a lateral flow immunoassay using a membrane.

[0024] The present invention also provides an immunoassay instrument that can perform immunoassay in a lateral flow manner using a monoclonal antibody that recognizes more than two types of antigens. The immunoassay instrument provided by the present invention is the following immunoassay instrument, which comprises: a support having a detection area with an antibody (antibody 1) that captures the assay object (antigen) solidified therein; a marker area having a movable labeled antibody (antibody 2); a sample pad for dripping the specimen; an absorption belt that absorbs the developed specimen liquid; and a packaging sheet for bonding these components into one, wherein at least one of the antibody 1 and the antibody 2 is a monoclonal antibody that recognizes more than two types of antigens of the present invention.

[0025] It should be noted that the number of detection regions and the type of labeled antibodies contained in the marker region are not limited to one, and by using antibodies corresponding to a plurality of measurement targets, two or more antigens can be detected using the same immunoassay instrument.

[0026] Figure 2This is a diagram showing a preferred embodiment of the immunochromatographic immunoassay device of the present invention. 1 indicates a support, 2 indicates a labeling region, 3 indicates a detection region, 4 indicates a sample pad, 5 indicates an absorption band, and 6 indicates a packaging sheet.

[0027] Figure 2 The top is a top view, and the bottom is a cut-off cross-sectional view. In the example of the figure, a support, an absorption band, a marker region, a sample pad, etc. having two detection regions are stacked on the packaging sheet. Moreover, as shown in the figure, one end of the absorption band overlaps with one end of the support, the other end of the support overlaps with one end of the marker region, and the other end of the marker region overlaps with one end of the sample pad, thereby forming a continuous lateral flow channel.

[0028] The support is a material having the ability to solidify the antibody used to capture the antigen, and has the ability to not hinder the passage of the liquid in the horizontal direction. It is preferably a porous film with capillary action, which is a material that can transport liquid and components dispersed in the liquid by absorption. There is no particular limitation on the material forming the support, and examples thereof include: cellulose, nitrocellulose, cellulose acetate, polyvinylidene fluoride (PVDF), glass fiber, nylon, polyketone, etc. Among them, a film made of nitrocellulose is more preferably used.

[0029] The marker region is composed of a porous substrate containing the labeled antibody, and the substrate can be made of commonly used glass fiber or nonwoven fabric, etc. In order to impregnate a large amount of labeled antibody, the substrate is preferably in a mat shape with a thickness of about 0.3 mm to 0.6 mm.

[0030] The detection region refers to a region of a portion of the support where antibodies that capture antigens are solidified. As for the detection region, it is preferred to set at least one region where monoclonal antibodies that recognize two or more antigens are solidified and to set a detection region for detecting labeled antibodies for actual auxiliary diagnosis.

[0031] The sample pad is a part for dripping the specimen or preparing the sample using the specimen, and is a porous material with water absorption. The material can be cellulose, glass fiber, non-woven fabric, etc. that are commonly used. In order to use a large amount of specimens for immunoassay, it is preferably in a pad shape with a thickness of about 0.3mm to 1mm. It should be noted that the sample pad and the aforementioned marker area are ultimately functionally different, and they do not necessarily have to be separate materials. That is, a part of the material used as the sample pad can also have the function of the marker area.

[0032] The absorption band is a member for absorbing the components supplied on the support and not participating in the reaction in the detection area. The material can be filter paper, sponge, etc. with high water retention composed of common natural polymer compounds, synthetic polymer compounds, etc., but in order to promote the development of the specimen, a material with high water absorption is preferred.

[0033] The packaging sheet is a member for adhering and fixing all the aforementioned materials, i.e., the support, sample pad, marker area, absorption band, etc., in a partially overlapping manner. Regarding the packaging sheet, it is not necessarily necessary as long as these materials, etc. are arranged and fixed at optimal intervals, but it is usually preferred to use it from the perspective of convenience in manufacturing or use.

[0034] Figure 2 In the immunoassay instrument of the method described in the specification, the specimen flows through a porous flow path formed by a series of connections of the sample pad, the marker area, the support, the detection area, the absorption band, etc. Therefore, in this method, all of these become the specimen movement area. Depending on the material or method of each constituent material, there may also be a method in which the specimen does not penetrate the inside of the material but passes through the interface, but the specimen movement area defined in this specification does not consider whether it is the inside of the material or the interface, so the immunoassay instrument of this method is also included in the scope of this specification.

[0035] based on Figure 2 The method of using the immunoassay instrument of the present invention is described in the following manner. The measurement is started by dropping the specimen or the sample prepared using the specimen onto the sample pad. Preferably, the specimen sample to be dropped is diluted in advance by about 2 to 20 times using a buffer solution containing a surfactant.

[0036] The specimen sample dripped onto the sample pad is spread out in the horizontal direction along the marker area, support, and absorption band due to capillary action. In the marker area, the labeled antibody is released into the solution along with the spread of the specimen sample and spreads toward the support. When an antigen is present in the specimen sample, the antigen is specifically captured by the capture antibody in the detection area of ​​the support, and the antigen also specifically reacts with the labeled antibody to form a complex. Thus, an antibody sandwich with the antigen in the middle is formed in the detection area, and the labeled antibody-antigen complex can be measured in the detection area.

[0037] As a monoclonal antibody with specificity that recognizes more than two types of antigens at the same time, it is believed that there may be various situations as follows: the situation of recognizing a region with high homology existing in different antigens, the situation of recognizing a region with similar three-dimensional structure existing in different antigens, the situation of recognizing a region that forms a complex with different antigens and spans its adjacent parts, the situation of recognizing a three-dimensional structure of a complex with different antigens and spanning its adjacent parts, etc., but it is more desirable that the two or more antigens recognized by a single monoclonal antibody are contained in the same complex. It should be noted that, here, "complex" refers to a collection of multiple molecules in the specimen due to certain effects. For example, when the subject is a bacterial cell, it can be considered that each antigen on the bacterial cell forms a complex. In the following examples, it is believed that the P1 protein and P30 protein of Mycoplasma pneumoniae form the "complex" mentioned here.

[0038] By being included in the same complex, the possibility of receiving steric hindrance between antibodies is reduced compared to the case where the antibodies exist as monomers, and the probability of achieving sandwich in the above-mentioned immunoassay is improved.

[0039] It is believed that the principle of improving the sensitivity of immunoassay by the method of the present invention is as follows. In the sandwich method, an antibody solidified on a solid phase is used, but the amount of antibody per unit area that can be solidified on the solid phase is limited. In addition, the time of antigen-antibody reaction is also limited. In particular, in immunochromatography, since the specimen or the sample (dilution of the specimen, etc.) prepared using the specimen only undergoes antigen-antibody reaction between flowing down from the upstream and flowing through the detection area, the antigen that fails to bind to the antibody during this time flows directly to the downstream of the detection area and cannot be detected. In the case where the amount of antigen in the specimen is small, as a solid-phase antibody, compared with the use of one type of monoclonal antibody that recognizes one type of antigen (the usual sandwich method), the amount of antigen bound to the antibody is increased when a monoclonal antibody that recognizes more than two types of antigens is used, so the sensitivity is improved. In addition, as a solid-phase antibody, when two types of monoclonal antibodies that recognize one type of antigen are used in combination, the amount of each monoclonal antibody that is solid-phased is half the amount of the entire solid-phase antibody. Therefore, when the time of the antigen-antibody reaction is short, the probability that a certain antigen and a monoclonal antibody that can bind to the antigen collide and bind in a specified direction is 1 / 2 compared to the case where all solid-phase antibodies are monoclonal antibodies that recognize the antigen. On the other hand, when a monoclonal antibody that recognizes more than two types of antigens is used, if any of the two or more antigens collides with the solid-phase antibody in a specified direction, the antibody will bind, so the amount of antigen captured by the solid-phase antibody is more than the case where two types of monoclonal antibodies that recognize one type of antigen are used in combination, and therefore, the sensitivity of the immunoassay is improved. Example

[0040] Hereinafter, the present invention will be described in more detail based on examples. Of course, the present invention is not limited to the following examples.

[0041] Example 1 Preparation of anti-Mycoplasma pneumoniae monoclonal antibodies 1. Modulation of Mycoplasma pneumoniae antigens Mycoplasma pneumoniae was cultured, and the culture solution was inactivated by heat treatment at 60°C for 30 minutes, and the inactivated product was used.

[0042] 2. Preparation of anti-Mycoplasma pneumoniae monoclonal antibodies BALB / c mice were immunized with the inactivated mycoplasma antigen of 1. The spleens were removed from the mice after being raised for a certain period of time and fused with mouse myeloma cells (P3×63) by the method of Kohler et al. (Kohler et al., Nature, vol, 256, p495-497 (1975)). The obtained fused cells (hybridomas) were maintained in an incubator at 37°C, and the antibody activity of the supernatant was confirmed by ELISA using a plate with a Mycoplasma pneumoniae P1 antigen and a plate with a Mycoplasma pneumoniae P30 antigen on a solid phase, and the cells were purified (monocloned).

[0043] As a result, as shown in Table 1, a plurality of hybridoma cell lines producing anti-Mycoplasma pneumoniae P1 antibody, anti-Mycoplasma pneumoniae P30 antibody, and anti-Mycoplasma pneumoniae P1-P30 antibody were obtained.

[0044] [Table 1] Clone Name Reactive antigen P1A P1 P1B P1 P30A P30 P30B P30 P1-P30A P1, P30 P1-P30B P1, P30 It should be noted that P1 and P30 used in this ELISA were prepared by gel filtration and ion exchange chromatography.

[0045] The obtained cell lines were intraperitoneally administered to BALB / c mice treated with pristane, and the ascites containing antibodies was collected about 2 weeks later. IgG was purified from the obtained ascites by affinity chromatography using a protein A column, and a plurality of purified anti-Mycoplasma pneumoniae monoclonal antibodies were obtained.

[0046] In the following examples, among the plurality of anti-Mycoplasma pneumoniae monoclonal antibodies obtained, antibodies selected in consideration of reactivity and antigenic epitope were used.

[0047] Example 2 Reactivity of anti-Mycoplasma pneumoniae monoclonal antibodies The reactivity of each monoclonal antibody obtained in Example 1 with Mycoplasma pneumoniae was confirmed by immunoblotting. Mycoplasma pneumoniae was cultured using PPLOBroth, and the culture solution was used as a sample.

[0048] The culture medium of Mycoplasma pneumoniae and molecular weight markers were subjected to SDS-PAGE electrophoresis using conventional methods. After electrophoresis, transfer to a PVDF membrane. After blocking with skim milk, wash thoroughly with PBS-Tween. The anti-P30 antibody adjusted to 1 μg / mL with PBS-Tween was reacted at room temperature for 1 hour. After washing thoroughly with PBS-Tween, the HRP-labeled anti-mouse antibody diluted to 3000 times was reacted at room temperature for 1 hour. After washing thoroughly with PBS-Tween, the signal was detected using ECL reagent (GE Healthcare) or POD immunostaining kit (Wako).

[0049] The results of immunoblotting are shown in Figure 1 .like Figure 1 As shown, the monoclonal antibodies obtained in Example 1 were confirmed to react specifically with each antigen in the same manner as the results of ELISA. Figure 1 The upper left graph (fluorescence detection by ECL) shows the results of P1A and P1B, the right lanes show the results of bacterial cells, and the left lanes show the molecular weight markers ( Figure 1 The same applies to the other figures in the figure). In each right lane, the band of the P1 protein is clear. Figure 1 The upper right graph (photographed using a densitometer after POD staining) shows the results for P30A and P30B. The band of the P30 protein is clear in each left lane. Figure 1 The lower left panel (photographed using a densitometer after POD staining) shows the results of P1-P30A. In the left lane, the bands of the P1 protein and the P30 protein are clear. Figure 1 The lower right panel (fluorescence detection by ECL reagent) shows the results of P1-P30B. The band of P30 protein is clear, and the band of P1 protein can also be confirmed but weakly.

[0050] Example 3 Immunoassay Instrument for Determining Mycoplasma Pneumoniae 1. Immobilization of Anti-Mycoplasma Pneumoniae Antibodies on Nitrocellulose Membranes A solution of the antibody prepared in Example 1 diluted with purified water to 1.0 mg / mL and an anti-mouse IgG antibody were prepared, and the antibody was applied in a line shape on the sample pad side of a nitrocellulose membrane lined with a PET film, and the anti-mouse IgG antibody was applied in a line shape on the absorbent side. Thereafter, the nitrocellulose membrane was dried at 45° C. for 30 minutes to obtain an anti-Mycoplasma pneumoniae antibody cured film. This is referred to as an antibody cured film in this example.

[0051] 2. Immobilization of Anti-Mycoplasma Pneumoniae Antibodies on Colored Polystyrene Particles The antibody prepared in Example 1 was diluted with purified water to 1.0 mg / mL, and colored polystyrene particles were added thereto to make it 0.1%, and after stirring, carbodiimide was added to make it 1%, and further stirred. The supernatant was removed by centrifugation, and resuspended in 50 mM Tris (pH 9.0), 3% BSA to obtain colored polystyrene particles bound to anti-Mycoplasma pneumoniae antibodies. In this example, they are called antibody-immobilized particles.

[0052] 3. Preparation of test strips for determination of Mycoplasma pneumoniae P1, P30 and P1 and P30 The antibody cured film prepared in 1 was laminated to other components (packaging sheet, absorbent tape, sample pad), and cut into 5 mm width pieces to prepare Mycoplasma pneumoniae test pieces (refer to Figure 2). These are referred to as test pieces in this embodiment.

[0053] Example 4, Comparative Example 1, Comparative Example 2 Comparison of the sensitivity of immunoassay instruments for measuring P1, P30, and P1 and P30 The monoclonal antibodies obtained in Example 1 were used in the combination shown in Table 2 by the procedure of Example 3 to prepare three types of test pieces: P1 test piece (Comparative Example 1), P30 test piece (Comparative Example 2), and P1-P30 test piece (Example 4).

[0054] [Table 2] 50 μL of a sample suspension containing an arbitrarily diluted Mycoplasma pneumoniae antigen and the antibody-immobilized particles prepared in 2 was dropped onto each test piece and allowed to stand for 15 minutes.

[0055] The case where color development could be visually confirmed at both the anti-mouse IgG antibody and the anti-Mycoplasma pneumoniae antibody application sites was judged as +. The case where color development could be visually confirmed only at the anti-mouse IgG antibody application site and color development could not be visually confirmed at the anti-Mycoplasma pneumoniae antibody application site was judged as -. In addition, the case where color development could not be visually confirmed at the anti-mouse IgG antibody application site was judged as invalid.

[0056] Table 3 shows the results of each test piece.

[0057] [Table 3] Blank x32 x64 x128 x256 x512 x1024 P1 test piece (Comparative Example 1) - + - - - - - P30 test piece (Comparative Example 2) - + + ± - - - P1-P30 test piece (Example 4) - + + + + + ± As shown in Table 3, the immunoassay apparatus of the present invention for measuring both P1 and P30 of Mycoplasma pneumoniae showed 16 times better sensitivity than the immunoassay apparatus for measuring P1 alone, and showed 8 times better sensitivity than the immunoassay apparatus for measuring P30 alone.

[0058] Example 5 The antibodies used in the P1-P30 test piece were combined with P1-P30A and P1-P30B in the same manner as in Example 4. The results showed 2 to 4 times higher sensitivity than the combination of P1-P30A alone (Example 4).

[0059] Explanation of symbols 1 Support 2 Marker section 3 Detection Area 4 Sample pads 5 Absorption bands Pack of 6 tablets.

Claims

1. A method for detecting a test object, wherein two or more antigens that can be detected as the test object exist, and the method is performed by an immunoassay method using a monoclonal antibody or an antigen-binding fragment thereof that recognizes the two or more antigens.

2. The method of claim 1, wherein: The monoclonal antibody or antigen-binding fragment thereof is used for at least one of a label or a solid phase, and the immunoassay method is a sandwich method.

3. The method of claim 2, wherein: The aforementioned immunoassay method is immunochromatography.

4. The method according to any one of claims 1 to 3, wherein The two or more antigens recognized by the monoclonal antibody form a complex.

5. The method according to any one of claims 1 to 4, wherein The aforementioned test object is Mycoplasma pneumoniae.

6. The method of claim 5, wherein: The two or more antigens are P1 protein and P30 protein.

7. An immunoassay device for performing the method according to claim 1, wherein the monoclonal antibody or the antigen-binding fragment thereof is used for at least one of a label or a solid phase. The immunoassay device according to claim 7, which is an immunochromatographic test piece.

9. The immunoassay instrument according to claim 7 or 8, wherein: The aforementioned test object is Mycoplasma pneumoniae.

10. The immunoassay instrument according to claim 9, wherein: The two or more antigens are P1 protein and P30 protein.

11. A monoclonal antibody that specifically reacts with the P1 protein and the P30 protein derived from Mycoplasma pneumoniae.